Semaglutide effects and safety, read first

Start here

Semaglutide effects fall into three buckets, and on this page the cautions come first. The benefits are real and well documented: less hunger, fewer cravings, weight loss, better blood sugar. The side effects are mostly about the gut — nausea is the big one, along with vomiting, diarrhea, constipation and burping — and they tend to be worst in the early weeks and after each dose increase. A small set of more serious warnings matters for specific people: a family history of a rare thyroid cancer, a history of pancreatitis, gallbladder problems, pregnancy, and pre-existing eye disease during rapid blood-sugar correction.

Below, the cited safety findings are read first, then the benefits, then a clearly-marked section of things people report that the trials have not confirmed. Nothing on this page tells anyone what dose to take — the figures are reported only as the studies recorded them.

Safety & cautions

These are the cited cautions, read before the benefits. Each is grounded in the published literature, and the harder warnings are flagged as warnings.

Gastrointestinal intolerance, especially during dose escalation. Nausea, vomiting, diarrhea and constipation are the dominant adverse effects in the trials and the leading reason people stop. In a pooled analysis of the weight-management program these events were predominantly mild-to-moderate and transient, concentrated around the titration period ^[8]; a dedicated safety review reported nausea in roughly one-third of patients ^[5], and real-world pharmacovigilance reporting is likewise dominated by gastrointestinal events ^[22]. This is clinical, not theoretical: the slowing of stomach emptying that underlies the gut effects is part of how the drug works.

Thyroid C-cell tumors (boxed warning). GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors derived from rodent studies, in which these tumors occurred at very high exposures. A 2024 assessment of thyroid carcinogenic risk concluded that available human data do not establish a clear increase in medullary or other thyroid cancer attributable to semaglutide ^[13][5] — so the thyroid-cancer signal is best framed as unconfirmed in humans. Even so, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a contraindication on the strength of the rodent finding.

Acute pancreatitis (class warning). Acute pancreatitis is a recognized class warning for this drug family, and treatment is conventionally stopped if pancreatitis is suspected. The dedicated safety review notes that pancreatic-cancer signals remain ones for which definitive conclusions cannot yet be drawn given their low incidence, rather than confirmed associations ^[5]. The caution is precautionary, not a demonstrated quantitative risk increase.

Gallbladder and biliary disease. The safety review found an increased risk of gallstone disease with semaglutide ^[5]. The effect is attributed largely to the rate and size of weight loss rather than a direct toxicity of the drug, but the increase versus placebo is a real finding, not merely theoretical.

Pre-existing diabetic retinopathy with rapid glucose correction. In SUSTAIN-6, rates of diabetic-retinopathy complications were significantly higher with semaglutide (HR 1.76; 95% CI 1.11–2.78), concentrated among patients with pre-existing retinopathy whose blood sugar was lowered quickly ^[2][5]. The leading interpretation is early worsening driven by the speed of correction rather than a direct toxic effect on the retina; monitoring is advised when blood sugar is corrected rapidly.

Weight regain after stopping. Stopping semaglutide is followed by substantial weight regain. In the STEP 1 trial extension, participants regained a mean of roughly 11.6 percentage points of body weight within one year of stopping, and cardiometabolic improvements reverted toward baseline ^[15]; the STEP 4 randomized-withdrawal trial likewise showed regain after switching to placebo ^[16]. This frames obesity drug therapy as ongoing rather than curative.

Pregnancy. Semaglutide is contraindicated in pregnancy. Because its elimination half-life is about one week, with effectively complete clearance only about five weeks after the last dose, label guidance advises stopping well in advance of a planned pregnancy (commonly cited as roughly two months) ^[19]. The half-life arithmetic is documented; the contraindication itself is a regulatory statement.

Drug interactions during titration. A systematic review of interactions between GLP-1 receptor agonists and oral medicines found the delayed stomach emptying these drugs cause generally does not produce clinically significant interactions, but advised monitoring for narrow-therapeutic-index oral drugs (medicines where the safe dose and the harmful dose are close together), especially during dose escalation ^[21]. The overall interaction risk is characterized as low.

Compounded semaglutide

Compounded semaglutide is a separate safety topic. During a federally declared shortage, compounding pharmacies were permitted to produce semaglutide; this is not the same as the approved manufactured product and falls outside its evidence base. The published safety review and the broader regulatory record emphasize that compounded or non-pharmaceutical sources carry documented quality and safety concerns, including dosing errors and unverified ingredients ^[5]. After the shortage was declared resolved in 2025, the compounding pathways were curtailed. The figures and findings throughout this site describe the approved, manufactured product as studied in the trials.

Semaglutide side effects

Pulling the cited record together: the common semaglutide side effects are gastrointestinal and concentrated early. Nausea is the most frequent, at roughly one in three patients in the dedicated safety review, alongside vomiting, diarrhea and constipation ^[5]; in the pooled weight-management analysis these were predominantly mild-to-moderate and transient, clustered around dose escalation rather than persistent, and accounted for most discontinuations ^[8]. Real-world pharmacovigilance reporting shows the same pattern, dominated by gastrointestinal events ^[22].

Less common but clinically important effects include increased gallbladder disease (cholelithiasis), attributed largely to the pace of weight loss ^[5]; loss of some lean mass alongside fat ^[14]; and weight regain after stopping ^[15]. The hard contraindications and class warnings — the boxed thyroid warning, acute pancreatitis, pregnancy, and retinopathy worsening with rapid glucose correction — are detailed in the cautions section above. The figures here are reported as the studies recorded them, not as advice.

What people report

The notes below are effects described by people using semaglutide in patient communities. They are anecdotal, not clinical evidence, and not verified by controlled trials. They are included for transparency, not as proof of anything, and no doses are attached to any of them.

Benefits people frequently describe. By far the most common is that the constant background chatter about food — what some call "food noise" — goes quiet, often within the first week or two; people say they feel full faster and stop thinking about the next meal. Many report that cravings for sugar, sweets and greasy or fried food drop sharply or disappear, with some naturally gravitating toward lighter meals. The large majority report weight loss, frequently steady and substantial over several months. People using it for type 2 diabetes commonly describe markedly better blood-sugar and A1C readings. A recurring secondary observation is that the urge to drink alcohol fades along with food cravings.

Adverse effects people report. Nausea is the single most reported side effect, mentioned by roughly a third of reviewers, sometimes escalating to vomiting at its worst; it tends to peak in the first weeks and after each dose increase and to flare after overeating or fatty food. A distinctive complaint is foul-smelling sulfur or "egg" burps, often after a dose increase, frequently with bloating. Disrupted bowel habits are common — both constipation and diarrhea, sometimes alternating. People also report acid reflux and heartburn, tiredness in the day or two after a dose, food aversions, a metallic taste, a heightened and unpleasant sensitivity to smells likened to morning sickness, headaches and lightheadedness (often linked to not drinking or eating enough), and mild injection-site reactions such as redness or a small bump. A smaller group reports increased hair shedding noticed a few months in, and a thinner, more hollow face — both widely attributed to losing weight quickly rather than to the medicine itself, and generally described as temporary.

Then and now

Semaglutide is the product of decades of incretin-peptide chemistry, built on an earlier GLP-1 medicine and engineered for once-weekly dosing through resistance to the enzyme DPP-4 and tight, reversible binding to albumin (a blood protein), which together let it circulate for about a week. It first reached FDA approval for type 2 diabetes in 2017, with an oral once-daily tablet following in 2019–2020 and a long-term weight-management indication in 2021 ^[1]. Its cardiovascular-outcomes evidence read out in SELECT in 2023 ^[3] and its kidney-outcomes evidence in FLOW in 2024 ^[6], with the corresponding indications approved in 2024 and 2025; a fatty-liver-disease (MASH) indication followed in 2025. During the declared shortage from roughly 2022 to early 2025, compounding pharmacies were permitted to produce semaglutide; that pathway was curtailed once the shortage was declared resolved ^[2].